CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,990 | -20.8% | 7,909 | -2.1% | 0.31% | -1.0% |
| Q2 2023 | $453,331 | +21.7% | 8,075 | -2.0% | 0.31% | -0.6% |
| Q1 2023 | $372,650 | +11.7% | 8,239 | +0.4% | 0.32% | +14.1% |
| Q4 2022 | $333,533 | -37.9% | 8,205 | -0.2% | 0.28% | -51.5% |
| Q3 2022 | $537,000 | +4.7% | 8,218 | -2.6% | 0.57% | +42.8% |
| Q2 2022 | $513,000 | -19.6% | 8,435 | +41.9% | 0.40% | -5.7% |
| Q3 2021 | $638,000 | -35.9% | 5,943 | -3.3% | 0.42% | -30.0% |
| Q2 2021 | $996,000 | -68.7% | 6,148 | +8097.3% | 0.61% | +20100.0% |
| Q1 2020 | $3,181,000 | -30.4% | 75 | 0.0% | 0.00% | -25.0% |
| Q4 2019 | $4,568,000 | +788.7% | 75 | -99.1% | 0.00% | -98.6% |
| Q1 1987 | $514,000 | – | 8,192 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |